Gilead Sciences’ Trodelvy treatment extended by three months the survival of patients with advanced stages of a common breast cancer, according to new data.
Gilead Sciences’ Trodelvy treatment extended by three months the survival of patients with advanced stages of a common breast cancer, according to new data.
